

LEHMAN & EILEN LLP  
50 Charles Lindbergh Blvd  
Suite 505  
Uniondale, NY 11553  
Tel: (516) 222-0888  
Fax: (516) 222-0915

April 28, 2008

*VIA EDGAR AND  
OVERNIGHT MAIL*

United States Securities  
and Exchange Commission  
100 F Street, NE  
Mail Stop 4561  
Washington, D.C. 20549  
Attention: Sonia Barros

*Re:   Pipex Pharmaceuticals, Inc.  
      File No. 001-12584*

Dear Ms. Barros:

Thank you for your April 25, 2008 letter regarding Pipex Pharmaceuticals, Inc.'s (the "Company") proxy statement. We hereby submit a letter responding to the two comments. For your convenience, we have set forth below the comments in their entirety followed by our responses thereto.

1. Please include the required compensation for 2006 in the summary compensation table.

Response: We will revise the summary compensation table to include the required compensation for 2006 in the Definitive Proxy Statement.

2. Please disclose your current plans to complete a spin off. If you have any plans to complete a spin off, you must provide all information that would be required as if the shareholders were voting on a spin off. See Note A to Schedule 14A.
-

Response: We will disclose in the Definitive Proxy Statement that “the Company has no plans to complete a spin off at this time.”

Please call me at (516)222-0888 to let me know whether I can file the Definitive Proxy Statement.

Thank you

Sincerely,

/s/ Steven Pappas

Steven Pappas

cc: Pipex Pharmaceuticals, Inc.